Generic Name and Formulations:
Nitroglycerin 0.4mg/spray; lingual pump spray.
Arbor Pharmaceuticals, LLC
Indications for NITROLINGUAL:
Acute attacks and prophylaxis of angina.
1–2 sprays at onset of attack, onto or under tongue while sitting; max 3 sprays/15 minutes. May use prophylactically 5–10 minutes before exertion. Do not inhale spray. Do not rinse mouth for 5–10 minutes after use.
Acute or recent MI. Hypotension. Monitor for tolerance. Hypertrophic cardiomyopathy. Avoid abrupt cessation. Volume depletion. Elderly. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Hypotension potentiated with sildenafil, alcohol, vasodilators, calcium channel blockers, other vasoactive drugs. Do not use epinephrine to treat hypotension from nitrate overdose.
Headache, dizziness, flushing, orthostatic hypotension, paresthesia, tachycardia, nausea, rash.
Spray—12g (200 metered sprays); 4.9g (60 metered sprays)
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds